from primary isolation plates and were streaked to blood agar plates that were incubated at 35°C for 24 h. Using a standard tube dilution procedure (9, 12), we confirmed that MICs for all isolates were below the accepted resistance breakpoint (2 ,ug/ml) for oxacillin. Correspondingly, as determined by the SIT and SBT testing described below, all isolates were found to have SIT values of -1:32.
Technical factor variations inherent in broth dilution methodology are known to influence significantly the results of MIC and MBC tests. In addition to the need for careful control of media, inoculum preparations, and incubation conditions, it has recently been demonstrated that dilutions should be carefully inoculated below the broth surfaces to avoid spuriously high MBC results, and that care should be taken to prevent antimicrobial-agent carryover from dilution tubes to avoid artifactually low MBC values (5, 12) . The technical steps for determining serum inhibition titer (SIT) and serum bactericidal titer (SBT) are similar to those used for determination of MIC and MBC. Although standards for media, inoculum preparation, and incubation conditions have been investigated and proposed (7, 9, 11) for SIT and SBT methodology, the potential production of spuriously low SBT values as a consequence of tube wall contamination and the production of factitiously high SBT values as a consequence of antimicrobial-agent carryover have not been evaluated. The present study investigates the potential influence of these latter two factors on SIT and SBT results.
MATERIALS AND METHODS Study design. SIT (Penase; Difco Laboratories, Detroit, Mich.) per plate, a quantity sufficient to rapidly inactivate >128 ,ug of oxacillin per ml (15) . For each tube in the SIT series, 100 ,ul was then removed and plated to separate sheep blood agar plates containing penicillinase. All colony count plates were incubated in air for 24 h at 35°C, and bacterial colonies were enumerated for each plate and compared with the base reference count.
Macro-B. The macro-A test described above was modified (macro-B) so that serum dilutions could be inoculated carefully and incubated along the lines suggested by Ishida and associates (5) and Taylor and associates (12) in their investigations of broth macrodilution MIC and MBC testing. One ml of each of the oxacillin-spiked pooled human serum dilutions prepared as described above in the tubes (16 Table 1 shows the distribution of SBT/SIT ratios for 30 oxacillin-susceptible S. aureus clinical isolates in parallel macro-A, macro-B, and microdilution tests without ,-lactamase added to count plates. Results for the less well controlled macro-A procedure show a moderate but distinct predominance of higher SBT/SIT ratios as compared with those obtained by the carefully controlled macro-B method. Additionally, SBT/SIT ratios for the microdilution method were distinctly lower and less dispersed than the macrodilution results. For the macro-A procedure, 27% of SBT interpretations were complicated by the occurrence of the irregular effect, a situation not encountered for either macro-B or microdilution. Table 2 presents the frequency distributions for SBT/SIT results, using parallel macro-A, macro-B, and microdilution tests and adding P-lactamase to count plates. The macrodilution SBT/SIT ratios were again somewhat larger and more disperse for the macro-A test than for the carefully controlled macro-B procedure. Both macro-A and macro-B results with penicillinase were slightly larger and more disperse than those summarized in Table 1 for the same tests without penicillinase. Tables 1 and 2 show that incorporation of penicillinase into the microdilution procedure produced a definite but small shift towards higher and more disperse SBT/SIT ratios. The irregular effect was notably increased for all three procedures when P-lactamase was used, a factor that was particularly evident for macro-B. DISCUSSION In 1947, Schlichter and MacLean (8) proposed SIT as a useful means of monitoring antimicrobial therapy. Five years later, Fisher (4) extended the test to include SBT. Since then, using many methodologic variations, millions of such tests have been performed in both investigative and clinical applications. In recent comprehensive reviews, Coleman and associates (3) and Wolfson and Swartz (14) have found little evidence to support the clinical usefulness of SIT and SBT testing and have stressed the need for future methodologic standardization and well-designed clinical trials for proper evaluation of what should be in theory a useful procedure. Coincident with the Wolfson and Swartz review, the results of a large collaborative study (13) were published, indicating that therapeutic success for treatment of endocarditis could be correlated with SBT peak values of .1:64 and trough values of .1:32, although lower values could not be correlated with either success or failure. Several centers were involved in the study, and SBT values were determined by a reportedly standardized microdilution test. The test was performed without P-lactamase incorporation and used a combination of human serum and MuellerHinton broth as the diluent. The latter had been shown (6, 7, 11) to be an acceptable medium, with buffering capacity similar to that of Mueller-Hinton agar and protein-binding capacity close to that of serum.
RESULTS
Because of analogous methodologies, SBT measurements can suffer from dependency on the same technical factor variations that have been shown to markedly affect MBC results. It has been demonstrated (5, 12) that spuriously high oxacillin MBCs are frequently produced for S. aureus isolates through the conventional macrodilution method. In contrast, spurious results are essentially eliminated when the following principles are incorporated into the technique: (i) use of log-phase inoculum, (ii) careful introduction of inoculum below the dilution broth surface, (iii) thorough mixing of dilution cultures after 20 h of incubation, (iv) thorough mixing at time of subculture to count plates after 24 h, and (v) addition of P-lactamase to count plates to prevent oxacillin carryover. Studies of microdilution applications for MBC testing have also demonstrated significant technical factor dependency (1, 2, 10, 16) , the effects of which can largely be eliminated by careful control of the same factors that influence macrodilution results. Despite the similarity of SBT and MBC methodologies, investigations concerning the influence of technical factor variations on SBT results have not yet been reported.
Our findings indicate that spuriously low SBT values occur more frequently and results are more disperse when technical factors are not carefully controlled for the macrodilution method. Spuriously low values were less frequently encountered and dispersion was less for microdilution than for other methods, suggesting that technical factor variations are inherently easier to control or perhaps are less significant for the microdilution approach. As compared with MBC results using similar methodologies (5, 12, 15) , both macrodilution and microdilution SBT results appear markedly less influenced by technical variations. This unexpected finding remains unexplained but could be related to the use of human serum in the SBT diluent mixture, in contrast to the conventional use of Mueller-Hinton broth for MBC tests. For both macrodilution and microdilution procedures, we found higher and less disperse SBT results when P-lactamase was not used.
A recent collaborative study on the therapeutic significance of high SBT values used a microdilution test, apparently similar to that used in the present study, although the exact technical details were not completely outlined in that report (13) . Our findings suggested that technical factor variations do not markedly influence microdilution SBT values; however, the tests done by Weinstein and associates were performed at several laboratories, suggesting the possibility of suboptimal control of technical variations. This factor may have resulted in an increased frequency of low values, a situation that could account for the failure to correlate low titers with therapeutic failure. Conversely, and compatible with our findings, failure to incorporate 13-lactamase into the test procedure may have shifted test results toward higher values, a situation that might account for the correlation of therapeutic success with somewhat higher peak and trough titers than those previously suggested by other investigations.
With careful control of methodologic variables and the addition of an appropriate ,3-lactamase to count plates, we demonstrated that reliable SBT values can be obtained by both the macrodilution and microdilution approaches, the latter being preferred on the basis of both reliability and technical simplicity. For patients on other than 1-lactam therapy, the inability to incorporate inactivating agents onto count plates should provoke the suspicion that SBT values may be artifactually high. The interpretation of results now remains the major problem. Subjectively attractive and difficult to argue against is the use of SBT to monitor successful conversion from intravenous therapy to oral therapy. For a specific disease process, results from the study by Weinstein and colleagues on endocarditis appear to provide the best guidelines to date (13) , but their results need confirmation and an improved interpretation of low and midrange values. For other infections, interpretive guidelines remain unestablished, and well-designed clinical investigations using carefully controlled methods are greatly needed.
